|
STAR-Echo: Software to Predict Cardiovascular Disease in Chronic Kidney Disease Patients
Application
A novel software for prognosis of MACE in chronic kidney disease patients using spatiotemporal analysis and transformer-based radiomics models.
Key Benefits
Unique interpretable features – identifies novel features based on longitudinal changes in LVW shape (perimeter & sphericity) and texture (intensity variations) over a...
Published: 2/13/2025
Contributor(s): Rohan Dhamdhere, Sadeer Al-Kindi, Gourav Modanwal, Anant Madabhushi
|
|
Mouse Model for Specific Proteomic Labeling
Application
Proteomic labeling (labeling of proteins).
Key Benefits
Method can be used to express TurboID in any cell type.
The mouse line can be crossed with any existing Cre line and can be extended to any organ/tissue system.
Detection of labeled biomarkers can be identified in biofluids as biomarkers of cell specific disease mechanisms.
Can...
Published: 2/13/2025
Contributor(s): Srikant Rangaraju, Nicholas (Nick) Seyfried, Sruti Rayaprolu
|
|
Markers Predictive of Therapeutic Response in B-cell Malignancies
Application
Test to detect NF-kB2 breaks to guide treatment with proteasome inhibitors and its use with other therapeutic agents.
Key Benefits
Improved the prediction model to determine which patients are more likely to respond to bortezomib treatment.
Improved the efficacy of treatment for patients with multiple myeloma and lymphomas.
Market...
Published: 2/13/2025
Contributor(s): Leon Bernal-Mizrachi
|
|
Assays for Labeling and Evaluating Lysine Methylation
Application
A life science tool for evaluating protein lysine methylation for drug discovery and disease research.
Key Benefits
Highly specific labeling method for post-translational methylated lysine.
Potential to improve the understanding of protein lysine methylation and help develop new drugs to block its interactions across several disease...
Published: 2/13/2025
Contributor(s): Monika Raj, Ogonna Nwajiobi
|
|
Blood-based Diagnostic Test for Anxiety
Application
A blood-based biomarker test for the diagnosis of anxiety disorders.
Key Benefits
Gene panel of at least seven biomarkers that may predict anxiety in humans.
Minimally invasive blood test.
May identify different forms of anxiety leading to personalized treatment and improved clinical outcomes.
Market Summary
Anxiety disorders are...
Published: 2/13/2025
Contributor(s): Reid Alisch, Pankaj Chopra
|
|
Method and System for Recording and Recovery of Electrophysiology During Stimulation
Application
Systems and methods for recording and recovering viable electrophysiological signals and during delivery of stimulation, including deep brain stimulation (DBS).
Key Benefits
Enables the recording of electrophysiology/neurophysiology during stimulation from the same stimulating contact and adjacent contacts.
Enables the potential usage...
Published: 2/13/2025
Contributor(s): Enrico Opri, Svjetlana Miocinovic
|
|
Predicting Treatment Response in Patients with Spinal Muscular Atrophy (SMA)
Application
Prognostic model predicts treatment response to nusinersen (Spinraza®) in patients with spinal muscular atrophy.
Key Benefits
A prediction model using baseline CHOP-INTEND, IL-8, fractalkine, and MCP-1 accurately predicts CHOP-INTEND outcomes in children treated with nusinersen
The model can also be incorporated into future therapeutic...
Published: 2/13/2025
Contributor(s): William Hu, Sumit Verma
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 2/13/2025
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
RNA Biomarkers for Alzheimer’s Disease
Application
RNA for U1 small nuclear ribonucleoprotein (snRNP) subunits as biomarkers for Alzheimer’s disease (AD).
Key Benefits
Identifies unique U1 snRNP pathology in AD patients that implicates abnormal RNA splicing in AD pathogenesis.
Facilitates early diagnosis and intervention strategies for treatment of AD.
Potential use as therapeutic...
Published: 2/13/2025
Contributor(s): Allan Levey
|
